178 related articles for article (PubMed ID: 19841674)
1. Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.
Bullock AN; Russo S; Amos A; Pagano N; Bregman H; Debreczeni JE; Lee WH; von Delft F; Meggers E; Knapp S
PLoS One; 2009 Oct; 4(10):e7112. PubMed ID: 19841674
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of low-nanomolar PIM kinase inhibitors.
Ishchenko A; Zhang L; Le Brazidec JY; Fan J; Chong JH; Hingway A; Raditsis A; Singh L; Elenbaas B; Hong VS; Marcotte D; Silvian L; Enyedy I; Chao J
Bioorg Med Chem Lett; 2015 Feb; 25(3):474-80. PubMed ID: 25575657
[TBL] [Abstract][Full Text] [Related]
3. Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors.
Bogusz J; Zrubek K; Rembacz KP; Grudnik P; Golik P; Romanowska M; Wladyka B; Dubin G
Sci Rep; 2017 Oct; 7(1):13399. PubMed ID: 29042609
[TBL] [Abstract][Full Text] [Related]
4. Structural comparison of human mammalian ste20-like kinases.
Record CJ; Chaikuad A; Rellos P; Das S; Pike AC; Fedorov O; Marsden BD; Knapp S; Lee WH
PLoS One; 2010 Aug; 5(8):e11905. PubMed ID: 20730082
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.
Holder S; Zemskova M; Zhang C; Tabrizizad M; Bremer R; Neidigh JW; Lilly MB
Mol Cancer Ther; 2007 Jan; 6(1):163-72. PubMed ID: 17218638
[TBL] [Abstract][Full Text] [Related]
6. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002.
Jacobs MD; Black J; Futer O; Swenson L; Hare B; Fleming M; Saxena K
J Biol Chem; 2005 Apr; 280(14):13728-34. PubMed ID: 15657054
[TBL] [Abstract][Full Text] [Related]
7. High-affinity inhibitors of human NAD-dependent 15-hydroxyprostaglandin dehydrogenase: mechanisms of inhibition and structure-activity relationships.
Niesen FH; Schultz L; Jadhav A; Bhatia C; Guo K; Maloney DJ; Pilka ES; Wang M; Oppermann U; Heightman TD; Simeonov A
PLoS One; 2010 Nov; 5(11):e13719. PubMed ID: 21072165
[TBL] [Abstract][Full Text] [Related]
8. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the ATPase domain of the human AAA+ protein paraplegin/SPG7.
Karlberg T; van den Berg S; Hammarström M; Sagemark J; Johansson I; Holmberg-Schiavone L; Schüler H
PLoS One; 2009 Oct; 4(10):e6975. PubMed ID: 19841671
[TBL] [Abstract][Full Text] [Related]
10. Using insights into Pim1 structure to design new anticancer drugs.
Schenone S; Tintori C; Botta M
Curr Pharm Des; 2010; 16(35):3964-78. PubMed ID: 21158732
[TBL] [Abstract][Full Text] [Related]
11. A flexible-protein molecular docking study of the binding of ruthenium complex compounds to PIM1, GSK-3β, and CDK2/Cyclin A protein kinases.
Liu Y; Agrawal NJ; Radhakrishnan R
J Mol Model; 2013 Jan; 19(1):371-82. PubMed ID: 22926267
[TBL] [Abstract][Full Text] [Related]
12. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
Pogacic V; Bullock AN; Fedorov O; Filippakopoulos P; Gasser C; Biondi A; Meyer-Monard S; Knapp S; Schwaller J
Cancer Res; 2007 Jul; 67(14):6916-24. PubMed ID: 17638903
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of the N-acetylmannosamine kinase domain of GNE.
Tong Y; Tempel W; Nedyalkova L; Mackenzie F; Park HW
PLoS One; 2009 Oct; 4(10):e7165. PubMed ID: 19841673
[TBL] [Abstract][Full Text] [Related]
14. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of pim1 kinase in complex with a pyrido[4,3-d]pyrimidine derivative suggests a unique binding mode.
Lee SJ; Han BG; Cho JW; Choi JS; Lee J; Song HJ; Koh JS; Lee BI
PLoS One; 2013; 8(7):e70358. PubMed ID: 23936194
[TBL] [Abstract][Full Text] [Related]
16. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
17. Indolyl-pyrrolone as a new scaffold for Pim1 inhibitors.
Olla S; Manetti F; Crespan E; Maga G; Angelucci A; Schenone S; Bologna M; Botta M
Bioorg Med Chem Lett; 2009 Mar; 19(5):1512-6. PubMed ID: 19179076
[TBL] [Abstract][Full Text] [Related]
18. The crystal structure of the Dachshund domain of human SnoN reveals flexibility in the putative protein interaction surface.
Nyman T; Trésaugues L; Welin M; Lehtiö L; Flodin S; Persson C; Johansson I; Hammarström M; Nordlund P
PLoS One; 2010 Sep; 5(9):e12907. PubMed ID: 20957027
[TBL] [Abstract][Full Text] [Related]
19. Ruthenium half-sandwich complexes bound to protein kinase Pim-1.
Debreczeni JE; Bullock AN; Atilla GE; Williams DS; Bregman H; Knapp S; Meggers E
Angew Chem Int Ed Engl; 2006 Feb; 45(10):1580-5. PubMed ID: 16381041
[No Abstract] [Full Text] [Related]
20. Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors.
Brown K; Long JM; Vial SC; Dedi N; Dunster NJ; Renwick SB; Tanner AJ; Frantz JD; Fleming MA; Cheetham GM
J Biol Chem; 2004 Apr; 279(18):18727-32. PubMed ID: 14766749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
